Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Sarah Brown, Gary Middleton, Tim Maughan, +17

The Lancet Oncology

Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial

Lisa Lowry, Paul Smith, Wendi Qian, +7

Radiotherapy and Oncology

Local ControlLymphoid NeoplasiaSurgical OncologyRadiation TherapyMedicine +7

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Fátima Cardoso, John M.S. Bartlett, Leen Slaets, +33

Annals of Oncology

Eortc 10085/Tbcrc/big/nabcgBreast OncologyMedicineGynecologyBreast Imaging +5

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier, +113

The Lancet

The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Julia Scarisbrick, Pietro Quaglino, H. Miles Prince, +102

British Journal of Dermatology

Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial

Rob Glynne‐Jones, David Sebag‐Montefiore, Helen Meadows, +9

The Lancet Oncology

The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology

Jesper Grau Eriksen, Andrew Beavis, Mary Coffey, +29

Radiotherapy and Oncology

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Marijn A. Vermeulen, Leen Slaets, Fátima Cardoso, +12

European Journal of Cancer

Pathological CharacterisationTumor BiologyEortc 10085/Tbcrc/big/nabcgBreast OncologyCancer Pathology +8

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

Mary Gleeson, Clare Peckitt, Ye To, +25

The Lancet Haematology

Radiation pneumonitis following treatment of non–small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART)

Peter Jenkins, Karen D’Amico, Kim Benstead, +1

International Journal of Radiation Oncology*Biology*Physics

Adaptive RadiotherapyNon–small-cell Lung CancerRadiation MedicineHealth SciencesRadiation Therapy +7